Short- and Long-Term Outcomes After Transcatheter Aortic Valve Implantation in Public and Private Hospital Settings: A Propensity-Matched Analysis.


Journal

Heart, lung & circulation
ISSN: 1444-2892
Titre abrégé: Heart Lung Circ
Pays: Australia
ID NLM: 100963739

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 11 12 2020
revised: 20 04 2021
accepted: 02 05 2021
pubmed: 11 7 2021
medline: 10 11 2021
entrez: 10 7 2021
Statut: ppublish

Résumé

To compare short- and long-term outcomes after transcatheter aortic valve implantation (TAVI) in the public and private hospital setting. Propensity-matched, retrospective analysis of a prospective registry. Patients with severe aortic stenosis who underwent TAVI at a tertiary public hospital (n=507) and an experienced private hospital (n=436). The primary endpoint was all-cause mortality. Patients that underwent TAVI in the public hospital were younger than patients in the private hospital (82±8 years vs 84±6 years, p<0.001), with lower estimated short-term mortality risk (Society of Thoracic Surgeons Predicted Risk of Mortality [STS-PROM] score >4.0%: 43% vs 56%, p<0.001). There was no difference between public and private hospitals in 30-day mortality (1.5% vs 1.2%, p=1.0), and the rate of complications was similar. Long-term survival was similar in propensity-matched public (n=344) and private (n=344) patient cohorts. The 1-year, 2-year, 5-year and 7-year survival rates were 95%, 90%, 67% and 47% in public patients, and 92%, 86%, 67% and 51% in private patients (p=0.94). In multivariable analysis, the hospital setting was not a predictor of mortality. Despite increased age and predicted mortality in private hospital patients, short- and long-term outcomes after TAVI were comparable between public and private hospital settings. This study demonstrates the feasibility of performing TAVI in a private hospital with a dedicated and experienced team and questions the current restricted access to TAVI in the private sector.

Identifiants

pubmed: 34244066
pii: S1443-9506(21)00542-4
doi: 10.1016/j.hlc.2021.05.083
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1910-1917

Informations de copyright

Copyright © 2021 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Auteurs

Pieter A Vriesendorp (PA)

Heart Centre, The Alfred Hospital, Melbourne, Vic, Australia; Department of Cardiology, Epworth Healthcare, Melbourne, Vic, Australia. Electronic address: pvriesendorp@gmail.com.

Shane Nanayakkara (S)

Heart Centre, The Alfred Hospital, Melbourne, Vic, Australia; Heart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne, Vic, Australia.

Joshua Bowditch (J)

Heart Centre, The Alfred Hospital, Melbourne, Vic, Australia.

Nay M Htun (NM)

Heart Centre, The Alfred Hospital, Melbourne, Vic, Australia.

Dion Stub (D)

Heart Centre, The Alfred Hospital, Melbourne, Vic, Australia; The School of Public Health and Preventive Medicine, Monash University, Melbourne, Vic, Australia.

Misha Dagan (M)

Heart Centre, The Alfred Hospital, Melbourne, Vic, Australia.

Julia Stehli (J)

Heart Centre, The Alfred Hospital, Melbourne, Vic, Australia; Department of Cardiology, Epworth Healthcare, Melbourne, Vic, Australia.

Ronald Dick (R)

Department of Cardiology, Epworth Healthcare, Melbourne, Vic, Australia.

Stephen J Duffy (SJ)

Heart Centre, The Alfred Hospital, Melbourne, Vic, Australia; The School of Public Health and Preventive Medicine, Monash University, Melbourne, Vic, Australia.

Antony S Walton (AS)

Heart Centre, The Alfred Hospital, Melbourne, Vic, Australia; Department of Cardiology, Epworth Healthcare, Melbourne, Vic, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH